Recent events
Recent events tied to this brand in public sources.
Back to profile3 entries
2026
Ipsen completes acquisition of Kartos Therapeutics
Ipsen announced on 21 August 2026 that it completed the acquisition of Kartos Therapeutics, a clinical-stage biopharmaceutical company, adding the late-stage MDM2 inhibitor navtemadlin, which is in Phase III clinical development for myelofibrosis.
2020
Ipsen announces Steven Hildemann as chief medical officer
Ipsen announced the appointment of Dr. Steven Hildemann as Executive Vice President, Chief Medical Officer, Head of Global Medical Affairs and Pharmacovigilance, effective March 1, 2020.
2019
Ipsen appoints Howard Mayer to lead R&D
Ipsen announced the appointment of Howard Mayer as Executive Vice President and Head of Research and Development, effective December 1, 2019. He succeeds Alexandre Lebeaut, who is to retire at the end of the year.